GLP-1 medications can shift how insurers evaluate recovery, credibility, and treatment needs
Melanie Avalon: Yeah, with the cyclodextrin, because they do talk in that paper about the possibly potential benefits of it as well, when you chose that compound, did you anticipate it having any other benefits, or was it more about just the mechanism of getting it into the cells
Who May Benefit Most From Long Term Use People with obesity, type 2 diabetes, insulin resistance, metabolic syndrome, or cardiovascular disease often benefit most from long term GLP-1 therapy
Whole-cell extracts expressing mito GCL revealed a super-shifted anti-GCL (1:1,000) band that was not present in the untagged GCL-expressing cells or in the mito GCL-transfected mitochondria (Fig